Why proteomics needs harder conversations (and more of them)
The next bottleneck in proteomics isn’t technical, it’s human. Faster...
It’s not a data problem, it’s a decision problem: 5 tips from Boston’s proteomics leaders
The discussion highlighted the field’s biggest bottlenecks - slow...
Stop Rolling the Dice: Why Proteomics Needs to Move Upstream in Drug Development
The single biggest reason drug discovery fails isn’t safety,...
From Lab Bench to Boardroom: Proteomics Comes of Age
Why now: Proteomics is breaking out of its niche. An unconventional...
Unlock Hidden Value: Integrate Proteomics and Drive Biology’s Next Leap
Discover why integrating proteomics data is biology’s next major...
Proteomics at a Crossroads: Why We Must Rethink Data Analysis
Proteomics is on the verge of a transformation. The depth and scale...
Pioneering Multivariate Companion Markers: Collaborative Pathways to Accelerate Market Access
Multivariate companion markers (MCMs) hold the key to unlocking...
Transforming Drug Discovery: The Critical Role of Proteomics and Targeted Protein Degradation in the Future of Therapeutics
Dr. Andrew I Webb explores how advanced proteomics and Targeted...
Coffees, conversations, and negotiations: an energizing day @ FeMS “Out Of The Shadows” Workshop
How we learnt to increase executive presence, harness the power of...
ASMS 2024: The rise of Automation and AI-Driven Raw MS Data Processing Solutions
72nd Conference on Mass Spectrometry and Allied Topics. Anaheim...
Proteomics Progression: Insights and Inflection Points
A Redwood City evening with Key Opinion Leaders, exploring insights...
What's New? Q2-23
More new features to breakthrough bottlenecks: protein abundance...
